Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Sarah Cannon Research Institute, Nashville, TN, United States

Survival: 8.6 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Nashville, TN
Hospital: Sarah Cannon Research Institute
Journal: Link
Date: 9/2010

This phase II study involved 57 patients with metastatic melanoma. The median age was 70 years and 68% of patients were male.

Patients were administered a combination of two biologic therapies bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) protein, and everolimus, an mTOR inhibitor. Both agents inhibit cancer cell division and stop blood vessel growth in tumors.

One death due to heart attack was reported for this study. Other toxicities reported were of grade 3 or less, the most common grade 3 toxicities being fatigue, stomatitis, and hypertension.

Median overall survival for this study was 8.6 months and median progression-free survival was 4 months.

This study was partially supported by Genentech and Novartis, makers of bevacizumab (brand name Avastin) and everolimus (brand name Afinitor), respectively.

Correspondence: Dr. John D. Hainsworth; email:

E-mail to a Friend Email Physician More Information